Revenue declined to USD 46.7 million from USD 62 million, as a result of decreased sales of infectious disease products due to a weak respiratory disease season. Total turnover from influenza products stood at USD 18.3 million, as a year-on-year drop in QuickVue Influenza product sales was offset to a certain extent by a 42% rise in Sofia Influenza revenue, which amounted to USD 6.2 million.
Total costs increased to USD 48.9 million in January-March 2014 from USD 44.8 million a year ago, chiefly owing to a change in the production volume and mix of products.
As a result, the firm recorded an operating loss of USD 2.2 million against a profit of 17.2 million in the first quarter of 2013.
(USD 1.0 = EUR 0.723)
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia